Earnings

Jasper Therapeutics Q2 EPS $(0.10) Beats $(0.26) Estimate

Aug 14, 2026 · 04:27 PM ET· updated 1h ago

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.26) by 61.54 percent. This is a 94.25 percent increase over losses of $(1.74) per share

Why It Matters

Jasper Therapeutics lost less money per share than experts thought it would—that's good news when a company is still in the losing phase. Watch this to see if the company is getting better at controlling its spending.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

JSPR0.75

-0.11 (-12.87%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.